OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/ROS1
Lung Cancer — Non-Small Cell (NSCLC)ROS1 Clinical Trials
ROS1 fusions are present in 1–2% of NSCLC and share clinical features with ALK-positive disease, including younger age at diagnosis and non-smoking history. Crizotinib and entrectinib have FDA approval for ROS1-positive NSCLC. Ongoing trials focus on overcoming acquired resistance and exploring novel selective ROS1 inhibitors with improved CNS penetration.
Top recruiting ROS1 Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 51 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Nuvation Bio Inc.